The Role of Gamma-Glutamyl Transferase in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Severity: A Cross-Sectional Study

Document Type : Original Article

Authors

1 Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran.

3 Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran.

Abstract

Introduction: Gamma-glutamyl transferase (GGT) is a liver enzyme that is involved in inflammation and oxidative stress. It has been hypothesized that elevated GGT may occur secondary to oxidative stress in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and can be used as an indicator of inflammation in these patients. The present study aimed to determine the relationship between serum GGT and arterial blood gas (ABGs) on the one hand and COPD severity in AECOPD patients on the other hand.
Methods: Patients with AECOPD were evaluated for disease severity based on the global initiative for chronic obstructive lung disease (GOLD), Modified British Medical Research Council (mMRC), COPD Assessment Test (CAT), and spirometry assessment upon admission at the hospital. Moreover, the GGT level in patients was analyzed based on the severity of the disease. The data were analyzed using SPSS software (version 25.0) by proper statistical tests. The significance level was P˂0.05.
Results: The mean±SD of the CAT score in the patients was obtained at 19.6± 4.6. According to the mMRC scale, most patients were grade 2 (n=29, 52.7%) and grade 1 (n=17, 30.9%), respectively. In addition, according to GOLD criteria, most patients (n=34, 61.8%) had moderate and severe (n=16, 29.1%) disease, respectively. The median (IQR) GGT levels in patients with mMRC 0-1 were 28.7 (12.98) IU/L, and those with mMRC 2-4 were 21 (33) IU/L (P=0.770). Additionally, the median (IQR) of GGT levels in patients in GOLD A-B were obtained at 26(18) IU/L, and in patients in GOLD C-D were reported as 18 (23.80) IU/L (P=0.222). The results showed a significant positive relationship between GGT level and AECOPD severity (r=+0.277, P=0.04). Moreover, a significant negative relationship was observed between GGT level and forced vital capacity (FVC) (r=-0.268, P=0.04). According to the Pearson correlation test, There was no significant correlation between GGT level with arterial HCO3 (P=0.123), PCO2 (P=0.511), PO2 (P=0.888), FEV1 (P=0.356), and FEV1/FVC (P=0.975).
Conclusion: In conclusion, while a significant positive relationship was found between GGT levels and AECOPD severity, the study suggests that serum GGT levels may not have clinical efficacy in differentiating between patients with varying intensities of AECOPD periods. Further research with larger sample sizes and consideration of additional factors is warranted to confirm these findings.

Keywords

References

  1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. American journal of respiratory and critical care medicine. 2017 Mar 1;195(5):557-82.
  2. Chhabra SK, Dash DJ. Acute exacerbations of chronic obstructive pulmonary disease: causes and impacts. Indian J Chest Dis Allied Sci. 2014 Jun;56(2):93-104.
  3. Wedzicha JA, Wilkinson T. Impact of chronic obstructive pulmonary disease exacerbations on patients and payers. Proceedings of the American Thoracic Society. 2006 May;3(3):218-21.
  4. Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. The Lancet Respiratory Medicine. 2017 Dec 1;5(12):956-67.
  5. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha J. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002 Oct 1;57(10):847-52.
  6. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 1998 May 1;157(5):1418-22.
  7. Hurst JR, Anzueto A, Vestbo J. Susceptibility to exacerbation in COPD. The Lancet Respiratory Medicine. 2017;5(9):e29.
  8. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091-7.
  9. Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Siafakas N. Prevalence and burden of comorbidities in chronic obstructive pulmonary disease. Respiratory investigation. 2016 Nov 1;54(6):387-96.
  10. Miri M, Badriahmadi S, Shamshirian A, Ghalibaf AM, Mozdourian M. Electrolyte Imbalance and COVID-19 Severity in Hospitalized Patients. Nephro-Urology Monthly. 2022 Dec 31(In Press).
  11. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American journal of respiratory and critical care medicine. 2007 Sep 15;176(6):532-55.
  12. Agustí García-Navarro À, Calverley PM, Celli BR, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respiratory Research, 2010, vol. 11, p. 122. 2010 Sep 10.
  13. Maio S, Baldacci SA, Martini F, Cerrai S, Sarno G, Borbotti M, et al. COPD management according to old and new GOLD guidelines: an observational study with Italian general practitioners. Current medical research and opinion. 2014 Jun 1;30(6):1033-42.
  14. Dhakal N, Lamsal M, Baral N, Shrestha S, Dhakal SS, Bhatta N, et al. Oxidative stress and nutritional status in chronic obstructive pulmonary disease. Journal of clinical and diagnostic research: JCDR. 2015 Feb;9(2):BC01.
  15. Abbasi B, Seyed Hosseini M, Moodi Ghalibaf A, Akhavan R, Emadzadeh M, Bolvardi E. Evaluating anemia on non-contrast thoracic computed tomography. Scientific Reports. 2022 Dec 10;12(1):21380.
  16. Gohel MG, Chacko AN. Serum GGT activity and hsCRP level in patients with type 2 diabetes mellitus with good and poor glycemic control: An evidence linking oxidative stress, inflammation and glycemic control. Journal of Diabetes & Metabolic Disorders. 2013 Dec;12:1-8.
  17. Radisic Biljak V, Rumora L, Cepelak I, Pancirov D, Popovic-Grle S, Soric J, et al. Gamma-glutamyltransferase and C-reactive protein in stable chronic obstructive pulmonary disease. Collegium antropologicum. 2013 Apr 3;37(1):221-7.
  18. Bozkus F, Dikmen N, Sahin H, Samur A. Serum gamma-glutamyl transferase activity as a potential novel cardiovascular biomarker in COPD. Respiratory Care. 2016 Nov 1;61(11):1465-71.
  19. Cepelak I, Dodig S, Romic D, Ruljancic N, Popovic-Grle S, Malic A. Enzyme catalytic activities in chronic obstructive pulmonary disease. Archives of medical research. 2006 Jul 1;37(5):624-9.
  20. Ermis H, Celik MR, Gulbas G, Tavli D, Aytemur ZA. Relationship between serum γ-glutamyltransferase levels and acute exacerbation of chronic obstructive pulmonary disease. Pol Arch Med Wewn. 2013 Jan 1;123(3):85-90.
  21. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha J. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999 Jul 1;54(7):581-6.
  22. Halpin DM, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2021 Jan 1;203(1):24-36.
  23. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy NK. Development and first validation of the COPD Assessment Test. European Respiratory Journal. 2009 Sep 1;34(3):648-54.
  24. Zinellu E, Zinellu A, Fois AG, Carru C, Pirina P. Circulating biomarkers of oxidative stress in chronic obstructive pulmonary disease: a systematic review. Respiratory research. 2016 Dec;17:1-1.
  25. Jones PW, Adamek L, Nadeau G, Banik N. Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. European Respiratory Journal. 2013 Sep 1;42(3):647-54.
  26. Arkhipov V, Arkhipova D, Miravitlles M, Lazarev A, Stukalina E. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. International journal of chronic obstructive pulmonary disease. 2017 Nov 3:3255-62.
  27. Haughney J, Gruffydd-Jones K, Roberts J, Lee AJ, Hardwell A, McGarvey L. The distribution of COPD in UK general practice using the new GOLD classification. European Respiratory Journal. 2014 Apr 1;43(4):993-1002.
Journal of Cardio-Thoracic Medicine
Volume 11, Issue 4
December 2023
Pages 1226-1236

Files

Share

How to cite

Statistics